Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Temozolomide - Merck & Co

Next Previous
X
Search
Drug Profile

Temozolomide - Merck & Co

Alternative Names: CCRG-81045; MB-39831; MK-7365; NSC-362856; RP-46161; SCH-52365; Temcad; Temodal; Temodar; Temomedac

Latest Information Update: 15 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cancer Research UK
  • Developer AbbVie; H. Lee Moffitt Cancer Center and Research Institute; MediciNova; Merck & Co; Schering-Plough; Stanford University; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Imidazoles; Small molecules; Triazenes
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Anaplastic astrocytoma; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic astrocytoma; Glioma; Malignant melanoma
  • Registered Ewing's sarcoma
  • Phase II Acute myeloid leukaemia; Breast cancer; Glioblastoma
  • No development reported Brain metastases; Gliosarcoma; Myelodysplastic syndromes; Non-small cell lung cancer; Small cell lung cancer
  • Discontinued Non-Hodgkin's lymphoma; Prostate cancer; Sarcoma

Most Recent Events

  • 31 May 2024 Efficacy data from a phase I/II trial in Glioblastoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 28 Jun 2023 H. Lee Moffitt Cancer Center and Research Institute in collaboration with Merck completes a phase I trial in Gliosarcoma and Glioblastoma (Newly diagnosed, Combination therapy) in USA (PO) (NCT03426891)
  • 21 Oct 2022 Phase-II clinical trials in Glioblastoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT05463848)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top